

(W:\20342\1202529\us1\00722866.DOC)

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered	04/12/2005
-----------------------	--------------------	------------

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0551-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/762,566-Conf. #3220
				Filing Date	January 23, 2004
				First Named Inventor	Richard Franklin
				Art Unit	3761
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	20342/1202529-US 1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (# known)	MM-DD-YYYY		


FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T
		Country Code <sup>2</sup> -Number <sup>1</sup> -Kind Code <sup>3</sup> (if known)	MM-DD-YYYY			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
AM		PESCATORE, <i>et al.</i> (2000). Anagrelide: a novel agent for the treatment of myeloproliferative disorders. <i>Exp. Opin. Pharmacother.</i> 1:537-46	
AM		GRIESSHAMMER, <i>et al.</i> (2001). Current treatment practice for essential thrombocythaemia in adults. <i>Exp. Opin. Pharmacother.</i> 2:385-93	
AM		LANE, <i>et al.</i> (2001). Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation. <i>Exp. Hematol.</i> 29:1417-24	
AM		ERUSALIMSKY, <i>et al.</i> (2002). Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5, 6-dichloro-3, 4-dihydroquinazoline (RL603)? <i>Exp. Hematol.</i> 30:625-8; author reply 626-7.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	04/12/20
-----------------------	---	--------------------	----------

NY 12034211202529us1100494298.DOC



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2008. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>			<b>Complete if Known</b>		
			Application Number	10/762,566-Conf. #3220	
			Filing Date	January 23, 2004	
			First Named Inventor	Richard Franklin	
			Art Unit	3761	
			Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	20342/1202529-US1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
<i>ad</i>	A1	US-6,585,995	07-01-2003	Hanson	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
		Country Code <sup>3</sup> -Number-Kind Code <sup>2</sup> (if known)				
<i>ad</i>	B1	WO-WO 2001/21259	03-29-2001	Emory University		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
<i>ad</i>	C1	Lane, et al. (1999) Anagrelide Metabolite Induces Thrombocytopenia in Mice by Inhibition of Megakaryocyte Maturation and Endoreplication Without Inducing Platelet Aggregation. <i>Blood</i> , 94:701a Supp. 1 (Part 1 of 2) [Abstract #3097]	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	<i>Richard Franklin</i>	Date Considered	04/12/2007
-----------------------	-------------------------	--------------------	------------

(W:20342)1202529us100439498.DOC (unofficial form)